|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Calquence
gptkb:Imbruvica
|
|
gptkbp:activities
|
inhibition of B-cell receptor signaling
|
|
gptkbp:affects
|
B-cells
|
|
gptkbp:approves
|
gptkb:healthcare_organization
mantle cell lymphoma
|
|
gptkbp:brand
|
gptkb:Calquence
gptkb:Imbruvica
Brukinsa
|
|
gptkbp:class
|
kinase inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:Waldenström's_macroglobulinemia
gptkb:chronic_graft-versus-host_disease
Phase II
Phase III
Phase I
relapsed/refractory CLL
|
|
gptkbp:example
|
gptkb:Zanubrutinib
gptkb:Ibrutinib
gptkb:Acalabrutinib
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bruton tyrosine kinase inhibitor
|
|
gptkbp:interacts_with
|
other signaling pathways
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_used_for
|
treatment of B-cell malignancies
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:temple
gptkb:Pharmacyclics
Bei Gene
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:origin
|
Bruton tyrosine kinase gene
|
|
gptkbp:price
|
high
|
|
gptkbp:project
|
clinical trials
|
|
gptkbp:research_areas
|
oncology
immunology
|
|
gptkbp:research_focus
|
biomarkers
combination therapies
resistance mechanisms
|
|
gptkbp:safety_features
|
monitored
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
hypertension
diarrhea
liver toxicity
rash
thrombocytopenia
cardiac arrhythmias
neutropenia
increased risk of infection
bleeding complications
|
|
gptkbp:social_structure
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:targets
|
gptkb:Bruton_tyrosine_kinase
|
|
gptkbp:year_created
|
2000s
|